Premium
A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma
Author(s) -
Pond Gregory R.,
Agarwal Neeraj,
Bellmunt Joaquim,
Choueiri Toni K.,
Qu Angela,
Fougeray Ronan,
Vaughn David,
James Nicholas D.,
Salhi Yacine,
Albers Peter,
Niegisch Günter,
Galsky Matthew D.,
Wong YuNing,
Ko YooJoung,
Stadler Walter M.,
O'Donnell Peter H.,
Sridhar Srikala S.,
Vogelzang Nicholas J.,
Necchi Andrea,
Di Lorenzo Giuseppe,
Sternberg Cora N.,
Mehta Amitkumar,
Sonpavde Guru
Publication year - 2014
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.12564
Subject(s) - medicine , nomogram , hazard ratio , confidence interval , oncology , response evaluation criteria in solid tumors , chemotherapy , progression free survival , performance status , odds ratio , urology , surgery , phases of clinical research
To study the impact of the prognostic factors liver metastasis (LM), anaemia (haemoglobin [Hb] <10 g/dL), Eastern Cooperative Oncology Group performance status (ECOG-PS) ≥1 and time from previous chemotherapy (TFPC) on the activity of second-line therapy for advanced urothelial carcinoma (UC).